13815-62-8

Basic information

• Product Name: Benzoic acid, 4-chloro-, 1-(4-methoxyphenyl)hydrazide, monohydrochloride
• CAS NO: 13815-62-8
• Molecular Formula: C14H13ClN2O2.ClH
• Molecular Weight: 313.183
• Mol File: 13815-62-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 4-chloro-, 1-(4-methoxyphenyl)hydrazide, monohydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 4-chloro-, 1-(4-methoxyphenyl)hydrazide, monohydrochloride(13815-62-8)
• EPA Substance Registry System: Benzoic acid, 4-chloro-, 1-(4-methoxyphenyl)hydrazide, monohydrochloride(13815-62-8)

Safety Data

• Hazardous Substances Data: 13815-62-8(Hazardous Substances Data)

Upstream product

• 122-01-0 4-chloro-benzoyl chloride 
• 13815-59-3 Acetaldehyd-N₁-(p-chlorbenzoyl)-p-methoxy-phenylhydrazon 
• 13815-71-9 1-ethylidene-2-(4-methoxyphenyl)hydrazine 

Downstream Products

• 22781-96-0 indomethacin 
• 23227-36-3 3-[1-(4-Chloro-benzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]-propionic acid 
• 1427215-00-6 4-(1-(4-chlorobenzoyl)-5-methoxy-3-methyl-1H-indol-2-yl)butanoic acid 
• 1427215-15-3 C₂₁H₂₀ClNO₄ 
• 1427215-16-4 2-(1-(4-chlorobenzoyl)-5-methoxy-2-propyl-1H-indol-3-yl)acetic acid 
• 1427215-01-7 C₂₁H₂₀ClNO₄ 
• 1427215-14-2 C₂₂H₂₁ClN₂O₅S 
• 36405-72-8 9-(4-chlorobenzoyl)-6-methoxy-2,3,4,9-tetrahydro-1H-carbazole-3-carboxylic acid 
• 53-86-1 [1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid 
• 1427215-02-8 C₂₂H₂₂ClNO₄ 
• 1427215-03-9 3-(1-(4-chlorobenzoyl)-5-methoxy-3-methyl-1H-indol-2-yl)-2-methylpropanoic acid 
• 1427215-04-0 C₂₂H₂₃ClN₂O₅S 
• 1412449-70-7 3-(1-(4-chlorobenzoyl)-5-methoxy-3-methyl-1H-indol-2-yl)-N-(methylsulfonyl)propanamide 
• 1427215-05-1 C₂₁H₁₈ClF₃N₂O₅S 

Relevant articles and documents

Bioisosteres of Indomethacin as Inhibitors of Aldo-Keto Reductase 1C3

Aldo-keto reductase 1C3 (AKR1C3) is an attractive target in drug design for its role in resistance to anticancer therapy. Several nonsteroidal anti-inflammatory drugs such as indomethacin are known to inhibit AKR1C3 in a nonselective manner because of COX-off target effects. Here we designed two indomethacin analogues by proposing a bioisosteric connection between the indomethacin carboxylic acid function and either hydroxyfurazan or hydroxy triazole rings. Both compounds were found to target AKR1C3 in a selective manner. In particular, hydroxyfurazan derivative is highly selective for AKR1C3 over the 1C2 isoform (up to 90-times more) and inactive on COX enzymes. High-resolution crystal structure of its complex with AKR1C3 shed light onto the binding mode of the new inhibitors. In cell-based assays (on colorectal and prostate cancer cells), the two indomethacin analogues showed higher potency than indomethacin. Therefore, these two AKR1C3 inhibitors can be used to provide further insight into the role of AKR1C3 in cancer.

Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity

The presently disclosed subject matter provides derivatives of non-steroidal anti-inflammatory drugs (NSAIDs) that are characterized by substantially reduced cyclooxygenase inhibiting activity, yet retain the ability to interact with and modulate the activities of other polypeptides such as the class of peroxisome proliferators-activated receptors (PPARs) and γ-secretase. Also provided are methods of using the derivatives to treat pathological disorders.